Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracyclineand/or taxane-based chemotherapy: Results of the Breast Cancer - Anemia and the Value of Erythropoietin (BRAVE) study

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 592-598

  Aapro, Matti ^a   Leonard, Robert C ^b   Barnadas, Agustí ^b   Marangolo, Maurizio ^b   Untch, Michael ^b   Malamos, Nikolaos ^b   Mayordomo, José ^b   Reichert, Dietmar ^b   Pedrini, José Luiz ^b   Ukarma, Lidia ^b   Scherhag, Armin ^b   Burger, Hans Ulrich ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; IRON; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HAZARD RATIO; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHATIC METASTASIS; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS;

EID: 39149121539     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.5378     Document Type: Article

References (25)

1. Barrett-Lee P, Bokemeyer C, Gascón P, et al: Management of cancer-related anemia in patients with breast or gynecologic cancer: New insights based on results from the European Cancer Anemia Survey. Oncologist 10:743-757, 2005
2. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999
3. Demetri GD, Gabrilove JL, Blasi MV, et al: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 3:45-51, 2002
4. Olsson AM, Svensson JH, Sundström J, et al: Erythropoietin treatment in metastatic breast cancer: Effects on Hb, quality of life and need for transfusion. Acta Oncol 41:517-524, 2002
5. Chang J, Couture F, Young S, et al: Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597-2605, 2005
6. Senecal FM, Yee L, Gabrail N, et al: Treatment of chemotherapy-induced anemia in breast cancer: Results of a randomized controlled trial of darbepoetin alfa 200 μg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 6:446-454, 2005
7. Caro JJ, Salas M, Ward A, et al: Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer 91:2214-2221, 2001
8. Antonadou D, Kardamakis E, Puglisi M, et al: Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: Final results of a randomized phase III study. Eur J Cancer 37:144, 2001 (suppl 6; abstr A530)
9. Glaser CM, Millesi W, Kornek GV, et al: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715, 2001
10. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
11. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
12. Bohlius J, Langensiepen S, Schwarzer G, et al: Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498, 2005
13. Rades D, Tribius S, Yekebas EF, et al: Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: Final results of a prospective observational study. Int J Radiat Oncol Biol Phys 65:459-465, 2006
14. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460, 2003
15. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
16. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
17. Bokemeyer C, Aapro MS, Courdi A, et al: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270, 2007
18. Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
19. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, v.2.2007: Cancer- and treatment-related anemia, version 3. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf
20. Österborg A, Brandberg Y, Hedenus M: Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 129:206-209, 2005
21. Aapro M, Coiffier B, Dunst J, et al: Effects of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 95:1467-1473, 2006
22. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, et al: Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: A meta-analysis. Anticancer Res 26:479-484, 2006
23. Hedenus M, Vansteenkiste J, Kotasek D, et al: Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23:6941-6948, 2005
24. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006
25. Crawford J, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895, 2002